JP7558170B2 - 腸内毒素症を減少させ、微生物叢を復元する方法 - Google Patents

腸内毒素症を減少させ、微生物叢を復元する方法 Download PDF

Info

Publication number
JP7558170B2
JP7558170B2 JP2021532282A JP2021532282A JP7558170B2 JP 7558170 B2 JP7558170 B2 JP 7558170B2 JP 2021532282 A JP2021532282 A JP 2021532282A JP 2021532282 A JP2021532282 A JP 2021532282A JP 7558170 B2 JP7558170 B2 JP 7558170B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
microbiota
subject
bacterial strains
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021532282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500489A (ja
JP2022500489A5 (https=
Inventor
ノーマン，ジェイソン
オレ，ベルナー
ロバーツ，ブルース
メノン，ラジータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vedanta Biosciences Inc
Original Assignee
Vedanta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedanta Biosciences Inc filed Critical Vedanta Biosciences Inc
Publication of JP2022500489A publication Critical patent/JP2022500489A/ja
Publication of JP2022500489A5 publication Critical patent/JP2022500489A5/ja
Priority to JP2024083941A priority Critical patent/JP7851353B2/ja
Application granted granted Critical
Publication of JP7558170B2 publication Critical patent/JP7558170B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/10—Detection mode being characterised by the assay principle
    • C12Q2565/101—Interaction between at least two labels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021532282A 2018-08-17 2019-08-16 腸内毒素症を減少させ、微生物叢を復元する方法 Active JP7558170B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024083941A JP7851353B2 (ja) 2018-08-17 2024-05-23 腸内毒素症を減少させ、微生物叢を復元する方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862765165P 2018-08-17 2018-08-17
US62/765,165 2018-08-17
US201862724185P 2018-08-29 2018-08-29
US62/724,185 2018-08-29
US201962815395P 2019-03-08 2019-03-08
US62/815,395 2019-03-08
US201962829513P 2019-04-04 2019-04-04
US62/829,513 2019-04-04
US201962829959P 2019-04-05 2019-04-05
US62/829,959 2019-04-05
PCT/US2019/046926 WO2020037271A1 (en) 2018-08-17 2019-08-16 Methods of decreasing dysbiosis and restoring a microbiome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083941A Division JP7851353B2 (ja) 2018-08-17 2024-05-23 腸内毒素症を減少させ、微生物叢を復元する方法

Publications (3)

Publication Number Publication Date
JP2022500489A JP2022500489A (ja) 2022-01-04
JP2022500489A5 JP2022500489A5 (https=) 2022-08-25
JP7558170B2 true JP7558170B2 (ja) 2024-09-30

Family

ID=69525842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532282A Active JP7558170B2 (ja) 2018-08-17 2019-08-16 腸内毒素症を減少させ、微生物叢を復元する方法
JP2024083941A Active JP7851353B2 (ja) 2018-08-17 2024-05-23 腸内毒素症を減少させ、微生物叢を復元する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024083941A Active JP7851353B2 (ja) 2018-08-17 2024-05-23 腸内毒素症を減少させ、微生物叢を復元する方法

Country Status (8)

Country Link
US (2) US12161680B2 (https=)
EP (1) EP3836946B1 (https=)
JP (2) JP7558170B2 (https=)
KR (1) KR20210091119A (https=)
CN (1) CN112888447A (https=)
AU (1) AU2019321681A1 (https=)
IL (2) IL280779B2 (https=)
WO (1) WO2020037271A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024119856A (ja) * 2018-08-17 2024-09-03 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
CA3226196A1 (en) 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
KR102503766B1 (ko) * 2020-06-16 2023-02-23 씨제이바이오사이언스 주식회사 장내 마이크로바이옴 지수를 결정하기 위한 장치, 방법 및 명령을 기록한 기록 매체
CN111796043B (zh) * 2020-08-15 2022-02-22 山东北大高科华泰制药有限公司 注射用盐酸罂粟碱粉针剂及其质量检测方法
WO2022159711A1 (en) 2021-01-21 2022-07-28 Vedanta Biosciences, Inc. Compositions and methods for treating hepatic encephalopathy
EP4362961A1 (en) * 2021-06-28 2024-05-08 Vedanta Biosciences, Inc. Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
JP2024540203A (ja) * 2021-11-08 2024-10-31 アルティメット メディシン アーゲー ミクログリア機能障害を治療し、代謝機能障害を改善するための方法および組成物
CN114496279B (zh) * 2022-01-12 2022-08-30 广州保量医疗科技有限公司 菌群移植配型的排序方法、系统、计算机设备及存储介质
EP4698197A1 (en) * 2023-04-20 2026-02-25 Ecole Polytechnique Federale De Lausanne (Epfl) AN ANTIBIOTIC AND A MICROORGANISM HAVING BILE ACID 7a-DEHYDROXYLATION ACTIVITY FOR TREATING NON-INFECTIOUS DISEASES
EP4704871A2 (en) * 2023-04-28 2026-03-11 Vedanta Biosciences, Inc. Compositions and methods for treating clostridioides difficile infection
WO2025076184A1 (en) 2023-10-03 2025-04-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
WO2025093778A1 (en) * 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota
CN119970806B (zh) * 2025-02-25 2026-03-03 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用
CN120779034A (zh) * 2025-07-15 2025-10-14 中山大学附属口腔医院 一种牙周炎相关标志物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
WO2017218680A1 (en) 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
WO2018080477A1 (en) 2016-10-26 2018-05-03 The Joan & Irwin Jacobs Technion-Cornell Institute Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols
US20180169153A1 (en) 2014-11-25 2018-06-21 Evelo Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft verses host disease

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
KR101260533B1 (ko) * 2005-03-03 2013-05-06 가부시키가이샤 메이지 면역기능 조정제
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
GB0916335D0 (en) * 2009-09-17 2009-10-28 Martin W J Medicaments
DK3564357T3 (da) * 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP3424515A3 (en) 2010-08-04 2019-06-19 Thomas Julius Borody Stool collection devices and methods for using them
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
MX359082B (es) 2011-05-23 2018-09-11 Washington State Univ Research Foundation Uso de agentes estabilizantes de pigmento fotosintético para regular la maduración y calidad de frutas y vegetales.
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
JP6201982B2 (ja) 2012-03-30 2017-09-27 味の素株式会社 糖尿病誘起細菌
US10130665B2 (en) 2012-05-18 2018-11-20 Genome Research Limited Method for identifying bacteria for bacteriotherapy
CN102743420A (zh) 2012-06-06 2012-10-24 上海交通大学 改善肠道菌群结构的方法及应用
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP2971148A4 (en) 2013-03-14 2016-08-17 Seres Therapeutics Inc METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
WO2014150094A1 (en) 2013-03-15 2014-09-25 University Of Florida Research Foundation, Inc. Butyrogenic bacteria as probiotics to treat clostridium difficile
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
CA2926466C (en) 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
AU2015244700B2 (en) 2014-04-10 2020-08-27 Riken Compositions and methods for induction of Th17 cells
EP3134509B1 (en) 2014-04-23 2026-01-21 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
US20170087196A1 (en) 2014-05-19 2017-03-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016086161A1 (en) 2014-11-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
BR112017024264B1 (pt) 2015-05-14 2022-07-12 Crestovo Holdings Llc Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração
EA201792547A1 (ru) 2015-05-21 2018-04-30 Иеда Рисеч Энд Девелопмент Ко. Лтд. Популяции бактерий для стимуляции состояния здоровья
WO2016201053A1 (en) 2015-06-09 2016-12-15 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
JP2018519295A (ja) 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性ｔ細胞の誘導
EP3319619A4 (en) 2015-07-08 2019-01-02 Seres Therapeutics, Inc. Methods of treating colitis
EP3341000A4 (en) 2015-08-24 2019-02-20 Nubyiota LLC SYSTEMS AND METHOD FOR TREATING DYSBIOSIS WITH BACTERIAL POPULATIONS FROM FECALIA
MX2018005107A (es) 2015-10-26 2018-08-09 Crestovo Holdings Llc Composiciones y metodos para la terapia relacionada con la microbiota fecal.
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3380108T3 (pl) 2015-11-24 2023-03-27 Seres Therapeutics, Inc. Zaprojektowane kompozycje bakteryjne
ME03487B (me) 2016-03-04 2020-01-20 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
CN109562147B (zh) 2016-06-28 2023-09-01 特里瓦生物制剂有限公司 保护微生物组免受口服抗生素
BR112020023933A2 (pt) 2018-05-24 2021-04-27 Seres Therapeutics, Inc. composições bacterianas projetadas e usos destas
AU2019321681A1 (en) * 2018-08-17 2021-02-25 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
WO2022159711A1 (en) 2021-01-21 2022-07-28 Vedanta Biosciences, Inc. Compositions and methods for treating hepatic encephalopathy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
US20180169153A1 (en) 2014-11-25 2018-06-21 Evelo Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft verses host disease
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
WO2017218680A1 (en) 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
WO2018080477A1 (en) 2016-10-26 2018-05-03 The Joan & Irwin Jacobs Technion-Cornell Institute Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024119856A (ja) * 2018-08-17 2024-09-03 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法
JP7851353B2 (ja) 2018-08-17 2026-04-24 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法

Also Published As

Publication number Publication date
US20220143108A1 (en) 2022-05-12
KR20210091119A (ko) 2021-07-21
WO2020037271A1 (en) 2020-02-20
IL280779A (en) 2021-04-29
CN112888447A (zh) 2021-06-01
JP2022500489A (ja) 2022-01-04
JP7851353B2 (ja) 2026-04-24
US20250161375A1 (en) 2025-05-22
JP2024119856A (ja) 2024-09-03
IL317775A (en) 2025-02-01
EP3836946B1 (en) 2026-04-22
US12161680B2 (en) 2024-12-10
IL280779B1 (en) 2025-01-01
AU2019321681A1 (en) 2021-02-25
EP3836946A1 (en) 2021-06-23
IL280779B2 (en) 2025-05-01
EP3836946A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
JP7558170B2 (ja) 腸内毒素症を減少させ、微生物叢を復元する方法
US11666612B2 (en) Network-based microbial compositions and methods
US11167018B2 (en) Compositions and methods for the induction of CD8+ T-cells
EP3468573B1 (en) Treatment of clostridium difficile infection
AU2019217041B2 (en) Compositions and methods for the induction of CD8+ T-cells
US20180296613A1 (en) Use of akkermansia muciniphila for treating inflammatory conditions
US11260083B2 (en) Compositions and methods for treating and preventing graft versus host disease
US20230158088A1 (en) Compositions for modulating gut microflora populations, enhancing drug potency and treating viral infections, and methods for making and using same
WO2008023663A1 (en) Bacterial strain having anti-allergic activity, and beverage, food and anti-allergic agent comprising cell of the bacterial strain
KR20200138333A (ko) 염증성 장 질환을 치료하는 조성물 및 방법
AU2024230804A1 (en) Compositions for modulating gut microflora populations, treatment of dysbiosis and disease prevention, and methods for making and using same
US20240173365A1 (en) Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease
CA3088505C (en) Compositions and methods for the induction of cd8+ t-cells
US20230127277A1 (en) Microbiome-based therapeutics
Heiss Interactions between the human milk oligosaccharide 2’-fucosyllactose and Bifidobacterium species influence colonization in complex gut communities
HK40007703A (en) Treatment of clostridium difficile infection
HK40007703B (en) Treatment of clostridium difficile infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240527

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240917

R150 Certificate of patent or registration of utility model

Ref document number: 7558170

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150